Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
Go back to Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments| Gilead Sciences (NASDAQ: GILD) | Delayed: 146.64 -4.35 (2.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.99 | 52 Week High | $108.63 | |||
| Open | $146.98 | 52 Week Low | $71.39 | |||
| Day High | $148.65 | P/E | 81.02 | |||
| Day Low | $145.45 | EPS | $1.81 | |||
| Volume | 6,080,505 | |||||
| NOVEN PHARMACEUTIC (NASDAQ: NOVN) | Delayed: 0.09 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.09 | 52 Week High | $23.79 | |||
| Open | $10.12 | 52 Week Low | $13.73 | |||
| Day High | $0.09 | P/E | 0.09 | |||
| Day Low | $0.09 | EPS | $1.05 | |||
| Volume | 1,574,031 | |||||
